University of California, San Francisco
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, University of California, San Francisco sits in the top decile of US sponsors by registered trial count (#10 of 15,742 sponsors by registered trial count).
University of California, San Francisco: 1,713 sponsored US clinical trials, 272 recruiting.
University of California, San Francisco sponsors 1,713 registered US clinical trials on ClinicalTrials.gov, 272 of them currently recruiting, and 1,130 completed. 196 of these trials are in Phase 3-4 (later-stage) and 359 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Breast Cancer, with 18 trials.
Top-decile sponsor footprint
University of California, San Francisco ranks in the top decile of sponsors by registered trial count (#10 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
1,130 of 1,305 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (86.6%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
1,713 total, page 12 of 35
Deciphering Principles of Network Dynamics Underlying Depression Symptom Severity From Multi-day Intracranial Recordings in Patients With Major Depression
NCT06953362
Effect of Methamphetamine on Residual Latent HIV Disease Study
NCT03825536
Randomized Study of Digital Life Coaching in Myeloma Patients Undergoing Transplantation
NCT04589286
Dexamethasone Solution and Dexamethasone in Mucolox™
NCT04540133
Program to Overcome Pelvic Pain Study
NCT04615247
Wire Instrumentation Using Radiofrequency Energy to Impact Transseptal Efficiency
NCT04645342
Daratumumab, Azacitidine, and Dexamethasone for Treatment of Patients With Recurrent or Refractory Multiple Myeloma Previously Treated With Daratumumab
NCT04407442
COVID-19 Citizen Science Expansion Project
NCT05548803
Fuerte Program for Newcomer Immigrant Youth
NCT04156373
Moving Together: An Online Group Movement Program for People Living With Memory Loss and Caregivers
NCT04621448
MBCT for People With Parkinson's Disease and Caregivers
NCT04469049
Tissue Immune Interaction in Nasal Polyposis
NCT04628442
Examine the Effects of Meditation on Daily Psychological Stress Responses in Woman With a History of Child Adversity
NCT04606199
Blood Lymphocytes in Asthmatics Treated With Therapeutic Proteins
NCT04514926
THC Crossover Study
NCT04429568
Pulmonary Specialist-Health Coach Consult Model Study
NCT03695276
Blood Flow Restriction After Meniscus Repair
NCT04436523
Non-invasive Transcranial Electrical Stimulation in MS
NCT04466228
Diet Education Program for Stage I-IV Colorectal Cancer Survivors
NCT04597151
A Distress Reduction Intervention for Patients With BCR-ABL-Negative MPNs or CML on Tyrosine Kinase Inhibitors
NCT04605211
mHealth ElectroNic COnsultation REcording (mENCORE) in Advanced Prostate Cancer
NCT04545697
Galcanezumab for Vestibular Migraine
NCT04417361
Predicting Inflammatory Skin Disease Response to IL-23 Blockade
NCT04541329
SweetDreams Sleep Study for Children With Autism
NCT04452045
Expanded Evaluation of the Survivorship Wellness Group Program in the Context of COVID-19 and Telehealth
NCT04630015
Encorafenib, Binimetinib, and Nivolumab in Treating Microsatellite Stable BRAF V600E Metastatic Colorectal Cancer
NCT04044430
Foster Care Mental Health Family Navigator
NCT04506437
Emergency Department Initiated Extended-Release Naltrexone and Case Management for the Treatment of Alcohol Use Disorder
NCT04094584
Ocrelizumab in Breastmilk
NCT04387110
A Pilot Randomized Controlled Trial of the Effects of Daily Skin-to-skin Contact (PRCTS2S)
NCT04368767
dHealth Solution for Improving Parent Adherence to Behavioral Treatment for ADHD
NCT04025814
Attachment and Biobehavioral Catch-up for Depression
NCT04050202
SCOPE-Chinese Women Study
NCT04326660
The No One Waits Study: Acceptability and Feasibility of Community-based Point-of-diagnosis HCV Treatment Study
NCT03987503
Neural Mechanisms of Meditation Training in Healthy and Depressed Adolescents: An MRI Connectome Study
NCT04254796
The Effect of Pectoral Blocks on Perioperative Pain in Gender Affirmation Top Surgery
NCT04474366
Rural Dementia Caregiver Project
NCT04428112
Evaluation of Survivorship Wellness Group Program for Patients Treated at University of California, San Francisco (UCSF)
NCT04636905
Digital Life Coaching for Myeloma Patients Undergoing Transplantation
NCT04432818
Impact of Breast Cancer Treatment on Joint Health, Cartilage Composition, and Bone Structure in the Knee and Hand
NCT04876378
Physical Activity and Fertility Care Study
NCT04002414
Using Technology to Reduce Youth Substance Use
NCT04446910
Engaging Sexual and Gender Minority Cigarette Smokers Into Social Media-based Treatment
NCT04461288
Hypoxia-Specific Imaging to Predict Outcomes of Chimeric Antigen Receptor T-cell Therapy
NCT04409314
COMPASS: A Group ACT Program for Cancer Patients Treated at UCSF
NCT04636346
Efficacy of Montelukast in Reducing the Incidence and Severity of Monoclonal Antibodies Associated Infusion Reactions
NCT04198623
COVID-19 PRIORITY (Pregnancy CoRonavIrus Outcomes RegIsTrY)
NCT04323839
Neonatal Seizure Registry - Developmental Functional EValuation
NCT04337697
Systemic and Topical Antivirals for Control of Cytomegalovirus Anterior Uveitis: Treatment Outcomes
NCT03586284
An Adaptive Intervention for Depression Among Latinos Living With HIV
NCT03668379
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 193 |
| Phase 2 | 166 |
| Phase 3 | 44 |
| Phase 4 | 152 |
Therapeutic Areas
What is open in the University of California, San Francisco pipeline
272 recruiting of 1,713 indexed (16% open); 1,130 completed (66%).
Phase mix: 196 late (III/IV) vs 359 early (I/II) (early-phase heavy).
Top condition: Breast Cancer (18 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
University of California, San Francisco: open-pipeline peers nationwide
Peers matched on 1,713 registered trials and 16% open enrollment, not the therapeutic-area sidebar.
University of California, San Francisco sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 1,713 trials (± recruiting share)
- Duke University · 1,725 trials · 11% recruiting
- Stanford University · 1,744 trials · 15% recruiting
- VA Office of Research and Development · 1,668 trials · 17% recruiting
- Pfizer · 1,845 trials · 6% recruiting
Sponsors near 16% open enrollment (± trial volume)
- University of Oregon · 16% recruiting · 63 trials
- Fox Chase Cancer Center · 16% recruiting · 183 trials
- Youngstown State University · 16% recruiting · 19 trials
- ECOG-ACRIN Cancer Research Group · 16% recruiting · 75 trials
Related
What to do with this University of California, San Francisco page
1,713 registered trials is a research-attention snapshot, not an endorsement of University of California, San Francisco or any single study.
- 272 of University of California, San Francisco's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Breast Cancer is the condition University of California, San Francisco studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Breast Cancer trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. University of California, San Francisco pipeline card: 1,713 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.